Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

2018957 citationsJournal Articlebronze Open Access

Authors

D. Ross Camidge · University of Colorado Cancer Center

Hye Ryun Kim · Yonsei University

Myung‐Ju Ahn · Samsung Medical Center

James Chih‐Hsin Yang · National Taiwan University Hospital

Ji‐Youn Han · National Cancer Center

Jong Seok Lee · Seoul National University Bundang Hospital

Maximilian J. Hochmair

Abstract

Among patients with ALK-positive NSCLC who had not previously received an ALK inhibitor, progression-free survival was significantly longer among patients who received brigatinib than among those who received crizotinib. (Funded by Ariad Pharmaceuticals; ALTA-1L ClinicalTrials.gov number, NCT02737501 .).

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Research Studies PI3K/AKT/mTOR signaling in cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 379, Issue 21, pp. 2027-2039

DOI: 10.1056/nejmoa1810171

Field-Weighted Citation Impact: 79.17